GHIT Fund Names Hiroki Nakatani as Board Chair

Thursday, June 7, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

TOKYO, June 7, 2018 /PRNewswire-USNewswire/ -- The Global Health Innovative Technology Fund (GHIT) today announced its appointment

of Hiroki Nakatani, MD, PhD, MHPEd, former World Health Organization (WHO) assistant director-general, to the fund's board of directors and named him its board chair. Nakatani succeeds founding GHIT Board Chair Kiyoshi
, who played an instrumental role in the fund's growth and achievements in its first five years of operation.

"Dr. Nakatani is a pioneer in global health and neglected tropical diseases, with an impeccable science and policy implementation track record. His unparalleled leadership in Japan and internationally in linking health innovation to effective policy and delivery will be critical as GHIT continues to evolve and as its first products hit the market," said BT Slingsby, CEO and executive director of the GHIT Fund. "Dr. Nakatani joins the board at a very exciting time as we've also just launched our second five-year phase. And we are grateful to Dr. Kurokawa for his invaluable contributions."

Nakatani served as WHO assistant director-general from 2007 to 2015, where he led the largest technical cluster comprising HIV/AIDS, tuberculosis, malaria and neglected tropical diseases. During his tenure, the morbidity and mortality of these diseases showed trends of decline, with some tropical diseases moving toward suppression and even eradication in the case of dracunculiasis (guinea worm disease).

Prior to joining WHO, Nakatani enjoyed a long career in Japan's Ministry of Health, Labour and Welfare, where he acquired extensive technical experience in public health, including immunization, health promotion, health emergencies and health workforce development. His senior-level responsibilities in the ministry included a focus on administration, management, and organizational and legislative development. He is currently a specially appointed professor at Keio University (Keio University Global Research Institute: KGRI), a specially appointed professor at Osaka University (in public health), an advisor for Japan's Ministry of Health, Labour and Welfare, a director at the National Center for Global Health and Medicine, and a WHO executive board member.

"I am honored to join the board of this transformational public-private partnership fund for global health R&D. GHIT is a catalytic force in Japan and across the globe, and it is overseen by highly talented, international and experienced governors. It is also humbling to succeed Kiyoshi Kurokawa, who led the GHIT Fund to success so deftly," said Nakatani.

As board chair, Nakatani will lead the operations and affairs of GHIT's board of directors, facilitate good governance, and lead board efforts to realize GHIT's mission and set future strategic direction.

"We conducted an exhaustive search for someone with deep experience in both international and Japanese global health leadership—someone who would further strengthen our board's breadth of talent and background. And we are delighted to have identified such an outstanding individual," said Kurokawa. "I'm confident that Dr. Nakatani is going to make an important and positive impact on the institution."

About the GHIT FundThe first of its kind in Japan, the GHIT Fund is an international public-private partnership between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome Trust and the United Nations Development Programme (UNDP). The GHIT Fund invests and manages a portfolio of development partnerships aimed at neglected diseases, such as HIV/AIDS, malaria, tuberculosis and neglected tropical diseases that afflict the world's poorest people. The GHIT Fund mobilizes Japanese pharmaceutical companies, academic and research organizations to engage in the effort to create new drugs, vaccines, and diagnostics. For more information, please visit

For more information, please visit

For more information, contact: Katy Lenard at +1-301-280-5719 or

Cision View original content:

SOURCE Global Health Innovative Technology Fund (GHIT Fund)

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store